Report: Americans' Opinions on Bioindustrial Manufacturing

BioMADE Releases New National Survey Showing Strong, Bipartisan Support for U.S. Leadership in Bioindustrial Manufacturing

Survey finds that the majority of Americans want more bio-based products, increased federal investment,

and strategic action to stay ahead of global competitors.


         

MINNEAPOLIS-ST. PAUL, MN/EMERYVILLE, CA, July 13, 2026 – Today, BioMADE released the results of a new national survey finding broad, bipartisan support for expanding America’s bioindustrial manufacturing capabilities. The results show that Americans across regions, demographics, and political affiliations overwhelmingly want more bio-based products in the supply chain, believe the federal government should invest in domestic biomanufacturing, and want the U.S. to fight to be a global leader in this competitive industry. 

Fifty-six percent of Americans say they want more American-made, bio-based products available on store shelves and in the supply chain, while only five percent disagree. Six in ten believe that the U.S. Government should invest in biomanufacturing research and production to reduce reliance on foreign supply chains and strengthen national competitiveness. Again, only five percent disagreed. Fifty-nine percent also say that the U.S. must fight to remain a global leader and avoid falling behind China, India, and the E.U. in biomanufacturing. 

 

“The results of this survey confirm what we are seeing and hearing across the country: bioindustrial manufacturing has the power to create jobs people want, support domestic supply chains, and reduce U.S. reliance on foreign imports. We are seeing massive global investments by governments across the globe including India, China, and across Europe. The majority of Americans aren’t only open to federal investment to win this critical industry, they are expecting it,” said Douglas Friedman, Chief Executive Officer at BioMADE.

 

Currently, China invests at least $4.3 billion annually in biomanufacturing and plans to build 20 pilot-scale plants by 2027. India is constructing over 20 new facilities and aims to double the economic impact of its biomanufacturing sector by 2030. And, the E.U. already has at least twice the fermentation capacity of the U.S. The majority of Americans recognize this gap and the urgency of closing it. Without quick and strategic action, the U.S. risks permanently losing its competitive advantage. 

 

Conducted in partnership with YouGov, the survey highlights a clear message: Americans want bio-based products, support government investment in biomanufacturing, and want to be a global leader in this industry. As the U.S. continues to build momentum in this industry, BioMADE remains committed to strengthening global competitiveness, advancing innovation, and ensuring the U.S. leads in this sector.

       


Download The Full Report

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS